Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Patients with type II diabetes mellitus are more susceptible to colorectal cancer (CRC) incidence than nondiabetics. The anti-diabetic drug metformin is most commonly prescribed for the treatment of this disease and has recently shown antitumor effect in preclinical studies. The aberrant mutational activation in the components of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathway is very frequently observed in CRC. We previously reported that metformin inhibits the phosphorylation of ERK and BEZ235, a dual inhibitor of PI3K and mTOR, has anti-tumor activity against HCT15 CRC cells harboring mutations of KRAS and PIK3CA. Therefore, we hypothesized that simultaneous inhibition of two pathways by combining metformin with BEZ235 could be more effective in the suppression of proliferation than single agent treatment in HCT15 CRC cells. Here, we investigated the combinatory effect of metformin and BEZ235 on the cell survival in HCT15 CRC cells. Our study shows that both of the two signaling pathways can be blocked by this combinational strategy: metformin suppressed both pathways by inhibiting the phosphorylation of ERK, 4E-BP1 and S6, and BEZ235 suppressed PI3K/AKT/ mTOR pathway by reducing the phosphorylation of 4E-BP1 and S6. This combination treatment synergistically reduced cell viability. The combination index (CI) values ranged from 0.44 to 0.88, indicating synergism for the combination. These results offer a preclinical rationale for the potential therapeutic option for the treatment of CRC.
Abstract
Patients with type II diabetes mellitus are more susceptible to colorectal cancer (CRC) incidence than nondiabetics. The anti-diabetic drug metformin is most commonly prescribed for the treatment of this disease and has recently shown antitumor effect in preclinical studies. The aberrant mutational activation in the components of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathway is very frequently observed in CRC. We previously reported that metformin inhibits the phosphorylation of ERK and BEZ235, a dual inhibitor of PI3K and mTOR, has anti-tumor activity against HCT15 CRC cells harboring mutations of KRAS and PIK3CA. Therefore, we hypothesized that simultaneous inhibition of two pathways by combining metformin with BEZ235 could be more effective in the suppression of proliferation than single agent treatment in HCT15 CRC cells. Here, we investigated the combinatory effect of metformin and BEZ235 on the cell survival in HCT15 CRC cells. Our study shows that both of the two signaling pathways can be blocked by this combinational strategy: metformin suppressed both pathways by inhibiting the phosphorylation of ERK, 4E-BP1 and S6, and BEZ235 suppressed PI3K/AKT/ mTOR pathway by reducing the phosphorylation of 4E-BP1 and S6. This combination treatment synergistically reduced cell viability. The combination index (CI) values ranged from 0.44 to 0.88, indicating synergism for the combination. These results offer a preclinical rationale for the potential therapeutic option for the treatment of CRC.
참고문헌 (34)
- Amado RG, "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", J Clin Oncol, 26, pp.1626~1634 (2008)
- Andreyeb HJN, "Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study", J Natl Cancer Inst, 90, pp.675~684 (1998)
- Bennouna J, "A phase II, open-label, randomized study to assess the efficacy and safety of the MEK1", 2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens, 2011, pp.29, 1021~1028
- Benvenuti S, "Oncogenic activation of the RAS", RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies, 2007, pp.67, 2643~2648
- Britten CB, "PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types", Cancer Chemother Pharmacol, 71, pp.1395~1409 (2013)
- Buzzai M, "Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth", Cancer Res, 67, pp.6745~6752 (2007)
- Chou TC, "Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher- order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors", Eur J Biochem, 115, pp.207~216 (1981)
- De Luca A, "The RAS", RAF, ERK and the PI3K, pp.AKT signaling pathways: Role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin Ther Targets[DOI]
- Garrett CR, "Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer", Br J Cancer, 106, pp.1374~1378 (2012)
- Gong J, "RAS and BRAF in metastatic colorectal cancer management", J Gastrointest Oncol, 7, pp.687~704 (2016)
- Griss T, "Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis", Plos Biol, 13, pp.e1002309~ (2015)
- Hsieh SC, "Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK", JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression, 2014, pp.46, 2809~2822
- Iliopoulos D, "Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types", Cancer Res, 71, pp.3196~3201 (2011)
- Larsson SC, "Diabetes mellitus and risk of colorectal cancer: A meta-analysis", J Natl Cancer Inst, 97, pp.1679~1687 (2005)
- 이재련, "Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells", 발생과 생식, 21(2), pp.139~150 (2017), 한국발생생물학회
- Lievre A, "KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer", Cancer Res, 66, pp.3992~3995 (2006)
- Liu P, "Targeting the phosphoinositide 3-kinase pathway in cancer", Nat Rev Drug Discov, 8, pp.627~644 (2009)
- Ma J, "Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma", BMC Cancer, 14, pp.172~182 (2014)
- MacKenzie T, "Diabetes and risk of bladder cancer: Evidence from a case-control study in New Zealand", Cancer, 117, pp.1552~1556 (2011)
- McCubrey JA, "Roles of RAF", MEK, Biochim Biophys Acta, pp.2007, 1773[DOI]
- Memmott RM, "Metformin prevents tobacco carcinogen-induced lung tumorigenesis", Cancer Prev Res, 3, pp.1066~1076 (2010)
- Mendoza MC, "The RAS-ERK and PI3K-mTOR pathways: Cross-talk and compensation", Trends Biochem Sci, 36, pp.320~327 (2011)
- Mihaylova MM, "The AMPK signaling pathway coordinates cell growth, autophagy and metabolism", Nat Cell Biol, 13, pp.1016~1023 (2011)
- Mohammed A, "Antidiabetic drug Metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling", Transl Oncol, 6, pp.649~659 (2013)
- Nangia-Makker P, "Metformin: A potential therapeutic agent for recurrent colon cancer", PLoS One, 9, pp.e84369~ (2014)
- Niehr F, "Combination therapy with vemurafenib (PLX4032", RG7204) and metformin in melanoma cell lines with distinct driver mutations, 2011, pp.9, 76~88
- 오일중, "Blockage of Autophagy Rescues the Dual PI3K", mTOR Inhibitor BEZ235- induced Growth Inhibition of Colorectal Cancer Cells, 2016, pp.20(1), 1~10[DOI]
- Posch C, "Combined targeting of MEK and PI3K", mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo, 2013, pp.110, 4015~4020
- Quinn BJ, "Repositioning metformin for cancer prevention and treatment", Trends Endocrinol Metab, 24, pp.469~480 (2013)
- Santarpia L, "Targeting of the MAPK-RAS-RAF signaling pathway in cancer therapy", Expert Opin Ther Targets, 16, pp.103~119 (2012)
- Shimizu T, "The clinical effect of the dualtargetingstrategy involving PI3K", AKT, MEK, pp.ERK pathways in patients with advanced cancer, Clin Cancer Res[DOI]
- Siegel RL, "Colorectal cancer statistics, 2017", CA Cancer J Clin, 67, pp.177~193 (2017)
- Tseng CH, "Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan", Eur J Endocrinol, 167, pp.409~416 (2012)
- Zhang HH, "Combinational strategies of metformin and chemotherapy in cancers", Cancer Chemother Pharmacol, 78, pp.13~26 (2016)